Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Neth Heart J ; 24(10): 609-16, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27561278

ABSTRACT

OBJECTIVE: Erythropoietin (EPO) improves cardiac function and induces neovascularisation in post-myocardial infarction heart failure. The aim of this study was to analyse the association between the serum erythropoietin level and coronary collateral development in patients with coronary artery disease and chronic total occlusion. METHODS: A total of 168 patients consisting of 117 with coronary artery disease (CAD, (62 with chronic total occlusion (CTO), 55 without CTO)) and 51 with healthy coronary arteries were included in the study. The patients were assigned as coronary artery disease without CTO (group 0), CAD with CTO (group 1: poor collateral development, group 2: good collateral development) and normal coronary arteries (group 3). RESULTS: There was a significant positive correlation between serum EPO levels and the Rentrop scores in angiography (r = 0.243, p = 0.001). Similarly, a positive correlation was found between serum EPO levels and the Syntax scores (r = 0.253, p = 0.001). Echocardiography revealed a negative correlation between serum EPO levels and the cardiac ejection fraction (r = -0.210, p = 0.006). CONCLUSIONS: Serum EPO is a useful biomarker for coronary collateral development in patients with CTO.

6.
Cardiovasc J Afr ; 23(4): 191-3, 2012 May.
Article in English | MEDLINE | ID: mdl-22614660

ABSTRACT

AIM: It has previously been shown that ß-blocker therapy reduces QT dynamics in heart failure patients. The aim of this study was to demonstrate this improvement with the third-generation ß-blocker, nebivolol. METHODS: A total of 72 heart failure patients with systolic dysfunction were included in the study. Corrected QT (QTc) and QT dispersion (QTcd) were measured manually by two independent observers at baseline and after nebivolol use (5 mg/day) in the first and third months of follow up. RESULTS: Both QTc and QTcd were found to be significantly reduced in the first (455.3 ± 26.7 vs 441.2 ± 25.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 58.2 ± 5.6 ms, p = 0.001 for QTcd) and third months (455.3 ± 26.7 vs 436.0 ± 28.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 56.0 ± 6.2 ms, p < 0.001 for QTcd) compared with baseline values. CONCLUSION: Nebivolol was associated with improved QT dynamics in heart failure patients with systolic dysfunction.


Subject(s)
Benzopyrans/therapeutic use , Electrocardiography/drug effects , Ethanolamines/therapeutic use , Heart Conduction System/physiopathology , Heart Failure/drug therapy , Ventricular Function, Left/drug effects , Adrenergic beta-Antagonists/therapeutic use , Aged , Female , Follow-Up Studies , Heart Conduction System/drug effects , Heart Failure/physiopathology , Humans , Male , Nebivolol , Platelet Aggregation Inhibitors , Treatment Outcome
7.
Cardiology ; 107(4): 233-8, 2007.
Article in English | MEDLINE | ID: mdl-16953108

ABSTRACT

OBJECTIVE: Coronary slow flow (CSF) is an angiographic phenomenon characterized by delayed opacification of coronary arteries in the absence of obstructive coronary disease. Recently, increased aortic pulse pressure (PP) and aortic pulsatility were both linked to the presence of angiographic coronary artery disease. In this study aortic PP and aortic pulsatility, derived from the invasively measured ascending aortic pressure waveform, were analyzed in patients with CSF and otherwise normal epicardial coronary arteries and compared with those with completely normal coronary arteries. METHODS: Fifty consecutive patients with CSF (35 men, mean age: 51.7 +/- 10 years) and fifty age and gender-matched controls (34 men, 51.1 +/- 9 years) were included in the study. For determination of coronary flow, the thrombosis in myocardial infarction (TIMI) frame count method was used. Blood pressure waveforms of the ascending aorta were measured during cardiac catheterization with a fluid-filled system. Aortic pulsatility was estimated as the ratio of aortic PP to mean pressure. RESULTS: Study groups were well matched with respect to age, gender and atherosclerotic risk factors. Although systolic, diastolic and mean pressures of the ascending aorta were similar, aortic PP (60.5 +/- 19 vs. 51.7 +/- 14 mm Hg, p = 0.01) and aortic pulsatility (0.63 +/- 0.1 vs. 0.54 +/- 0.1, p = 0.006) were significantly higher in patients with CSF compared with the controls. Besides, in all subjects, corrected TIMI frame counts of all three coronary arteries correlated with both ascending aorta PP and aortic pulsatility values. No association was found between corrected TIMI frame counts of coronary arteries and aortic mean blood pressure or brachial blood pressure parameters. CONCLUSION: Our findings suggest that CSF is, as with obstructive coronary artery disease, associated with more diffuse vascular disease rather than being an isolated finding.


Subject(s)
Aorta/physiopathology , Aortic Diseases/complications , Coronary Artery Disease/physiopathology , Adult , Aorta/physiology , Blood Pressure , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/etiology , Female , Humans , Male , Middle Aged , Pulsatile Flow
SELECTION OF CITATIONS
SEARCH DETAIL
...